• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Letter comments on: Efficacy and safety of BNT162b2 vaccination in solid cancer patients receiving anti-cancer therapy - A single-centre prospective study: Interaction between lymphopenia and anti-SARS-CoV-2 antibodies after two injections of the Pfizer-BioNTech vaccine in patients with cancers treated by chemotherapy or immunotherapy.

作者信息

Sekkate Sakina, Stoeklé Henri-Corto, Mabro May, Billard David, Kennel Titouan, Vasse Marc, Hervé Christian, Beuzeboc Philippe

机构信息

Oncology and Supportive Care Department, Foch Hospital, Suresnes, France.

Department of Ethics and Scientific Integrity, Foch Hospital, Suresnes, France.

出版信息

Eur J Cancer. 2022 Jan;160:282-284. doi: 10.1016/j.ejca.2021.09.048. Epub 2021 Oct 28.

DOI:10.1016/j.ejca.2021.09.048
PMID:34810045
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8552578/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a202/8552578/3dc5586f9678/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a202/8552578/3dc5586f9678/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a202/8552578/3dc5586f9678/gr1_lrg.jpg

相似文献

1
Letter comments on: Efficacy and safety of BNT162b2 vaccination in solid cancer patients receiving anti-cancer therapy - A single-centre prospective study: Interaction between lymphopenia and anti-SARS-CoV-2 antibodies after two injections of the Pfizer-BioNTech vaccine in patients with cancers treated by chemotherapy or immunotherapy.关于《BNT162b2疫苗在接受抗癌治疗的实体癌患者中的疗效和安全性——一项单中心前瞻性研究：化疗或免疫治疗的癌症患者接种两剂辉瑞-BioNTech疫苗后淋巴细胞减少与抗SARS-CoV-2抗体之间的相互作用》的信函评论
Eur J Cancer. 2022 Jan;160:282-284. doi: 10.1016/j.ejca.2021.09.048. Epub 2021 Oct 28.
2
Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia.辉瑞/生物科技和牛津/阿斯利康疫苗对沙特阿拉伯全国疫苗接种运动中真实环境下 COVID-19 发病率和死亡率的影响。
Eur Rev Med Pharmacol Sci. 2021 Nov;25(22):7185-7191. doi: 10.26355/eurrev_202111_27271.
3
[Immune thrombocytopenia after BNT162b2 mRNA COVID-19 vaccination].[BNT162b2 mRNA新冠疫苗接种后免疫性血小板减少症]
Rinsho Ketsueki. 2021;62(11):1639-1642. doi: 10.11406/rinketsu.62.1639.
4
Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.立陶宛血液系统恶性肿瘤患者的 BNT162b2 COVID-19 mRNA 疫苗免疫原性和早期临床结局：一项全国前瞻性队列研究。
Lancet Haematol. 2021 Aug;8(8):e583-e592. doi: 10.1016/S2352-3026(21)00169-1. Epub 2021 Jul 2.
5
COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.COVID-19 疫苗：辉瑞/生物科技和 Moderna 疫苗的生物学、药理学特征和不良反应比较。
Eur Rev Med Pharmacol Sci. 2021 Feb;25(3):1663-1669. doi: 10.26355/eurrev_202102_24877.
6
Robust Antibody Levels in Both Diabetic and Non-Diabetic Individuals After BNT162b2 mRNA COVID-19 Vaccination.BNT162b2 mRNA新冠疫苗接种后糖尿病和非糖尿病个体均产生强劲抗体水平。
Front Immunol. 2021 Nov 24;12:752233. doi: 10.3389/fimmu.2021.752233. eCollection 2021.
7
Comparative Effectiveness and Antibody Responses to Moderna and Pfizer-BioNTech COVID-19 Vaccines among Hospitalized Veterans - Five Veterans Affairs Medical Centers, United States, February 1-September 30, 2021.美国五家退伍军人事务医疗中心 2021 年 2 月 1 日至 9 月 30 日期间住院退伍军人中 Moderna 和辉瑞-BioNTech COVID-19 疫苗的有效性和抗体反应比较。
MMWR Morb Mortal Wkly Rep. 2021 Dec 10;70(49):1700-1705. doi: 10.15585/mmwr.mm7049a2.
8
Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment.抗肿瘤治疗的癌症患者接种 BNT162b2 冠状病毒病 2019 信使 RNA 疫苗后体液免疫应答降低。
ESMO Open. 2021 Oct;6(5):100274. doi: 10.1016/j.esmoop.2021.100274. Epub 2021 Sep 8.
9
Immune Response after SARS-CoV-2 Vaccination in Kidney Transplant Patients.肾移植患者接种 SARS-CoV-2 疫苗后的免疫反应。
Medicina (Kaunas). 2021 Dec 3;57(12):1327. doi: 10.3390/medicina57121327.
10
High seroconversion rate but low antibody titers after two injections of BNT162b2 (Pfizer-BioNTech) vaccine in patients treated with chemotherapy for solid cancers.实体癌化疗患者接种两剂BNT162b2（辉瑞-生物科技公司）疫苗后血清转化率高但抗体滴度低。
Ann Oncol. 2021 Oct;32(10):1294-1295. doi: 10.1016/j.annonc.2021.06.018. Epub 2021 Jun 22.

引用本文的文献

1
BNT162b2 COVID-19 Vaccines in Children, Adolescents and Young Adults with Cancer-A 1-Year Follow-Up.BNT162b2新冠疫苗在患有癌症的儿童、青少年和年轻人中的应用——1年随访
Vaccines (Basel). 2023 May 16;11(5):989. doi: 10.3390/vaccines11050989.
2
From a voluntary vaccination policy to mandatory vaccination against COVID-19 in cancer patients: an empirical and interdisciplinary study in bioethics.从自愿接种疫苗政策到癌症患者强制接种 COVID-19 疫苗：生物伦理学中的实证和跨学科研究。
BMC Med Ethics. 2022 Aug 28;23(1):88. doi: 10.1186/s12910-022-00827-3.
3
Seropositivity and neutralising antibodies at six months after BNT162b2 vaccination in patients with solid tumours.
接受 BNT162b2 疫苗接种 6 个月后实体瘤患者的血清阳性率和中和抗体。
Eur J Cancer. 2022 Jun;168:51-55. doi: 10.1016/j.ejca.2022.03.013. Epub 2022 Apr 16.